Acumen Pharmaceuticals to Report Third Quarter 2022 Financial Results on Nov. 14, 2022
08 November 2022 - 8:01AM
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage
biopharmaceutical company focused on the development of novel
targeted therapeutics for Alzheimer’s disease, today announced that
the Company will report its financial results for the third quarter
2022 on Monday, November 14, 2022. The Company will host a
conference call and live audio webcast at 4:30 p.m. ET to provide a
business and financial update.
To participate in the live conference call, please register
using this link. After registration, you will be informed of
the dial-in numbers including PIN. Please register at least one day
in advance.
The audio webcast will be available via this link.
An archived version of the webcast will be available for at
least 30 days in the Investors section of the Company's website at
www.acumenpharm.com.
About Acumen Pharmaceuticals, Inc.
Acumen, headquartered in Charlottesville, VA,
with clinical operations based in Carmel, IN, is a clinical stage
biopharmaceutical company developing a novel disease-modifying
approach to treat Alzheimer’s disease. Acumen’s scientific founders
pioneered research on AβOs, which a growing body of evidence
indicates are primary triggers of Alzheimer’s disease pathology.
Acumen is currently focused on advancing its investigational
product candidate, ACU193, a humanized monoclonal antibody that
selectively targets toxic soluble AβOs in INTERCEPT-AD, a Phase 1
clinical trial involving early Alzheimer’s disease patients. For
more information, visit www.acumenpharm.com.
Investors: Alex Braunabraun@acumenpharm.com
Media: AcumenPR@westwicke.com
Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From Apr 2023 to Apr 2024